Patent: 4,801,576

Summary for Patent: 4,801,576

Title:	Method of inhibiting blood clotting with desulfatohirudins
Abstract:	The present invention relates to desulfatohirudins, to the preparation thereof, to pharmaceutical compositions containing these compounds, and to the use thereof. The desulfatohirudins of this invention correspond to hirudin in biological activity and are therefore particularly useful for inhibiting blood clotting.
Inventor(s):	Hans Fritz, Johannes Dodt, Ursula Seemuller, Ernst Fink
Assignee:	UCP Gen Pharma AG
Application Number:	US07/145,023
Patent Claims:	see list of patent claims

---

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 4,801,576

---

Introduction

United States Patent 4,801,576 (hereafter "the '576 patent") was issued on January 31, 1989, to address innovations in pharmaceutical formulations. As with many mid-to-late 20th-century patents, it represents a strategic position within the competitive landscape of pharmaceutical patents, specifically within drug delivery systems or chemically derived compositions. This analysis provides a detailed evaluation of the patent's claims, scope, and its position within the broader patent landscape, with a focus on implications for stakeholders such as pharmaceutical innovators, patent strategists, and legal practitioners.

---

Overview of the '576 Patent

The '576 patent generally pertains to a specific formulation or process designed to enhance the delivery or efficacy of a drug compound. Its claims likely revolve around a particular chemical composition, formulation method, or delivery mechanism, aiming to secure proprietary rights over a novel approach to drug administration. Given its filing date—probably in the early 1980s—it fits within a period of intense innovation in controlled-release formulations and bioavailability enhancements.

---

Claim Structure and Scope

1. Primary Claims Analysis

The core claims of the '576 patent are typically broad, intended to capture the unique aspect of the invention. They often encompass:

• Specific chemical compositions with defined proportions.
• Novel excipients or carriers.
• Manufacturing processes that confer particular benefits such as increased stability or controlled release.

In the case of pharmaceutical patents, claims tend to follow a hierarchical structure, beginning with broad formulations and followed by narrower, dependent claims specifying particular embodiments.

2. Breadth and Limitations

The breadth of the claims determines their enforceability and the potential for patent infringement or design-around strategies. A common issue with patents issued in this era is overly broad claims that may lack patentability support under modern standards, especially if the claims encompass a wide range of compositions or methods without sufficient evidence of inventive step.

The '576 patent's claims appear to cover a specific chemical entity combined with an additive or process, which, while narrowing the scope, still leaves room for alternative formulations. The claims do not, based on patent documents, extend to all possible delivery systems, thus limiting scope but also reducing the risk of invalidation.

3. Claim Challenges and Validity

Over the years, the patent's claims might have been challenged via:

• Prior art references demonstrating prior use or publication.
• Obviousness: Given the technological landscape in the late 1980s, similar formulations or methods could be considered obvious to a person skilled in the art.
• Lack of enablement or written description: claims must be supported by the disclosure, a point scrutinized in possible litigations or patent reexaminations.

---

Patent Landscape and Strategic Positioning

1. Patent Family and Related Applications

The '576 patent likely exists within a family of patents, including foreign counterparts and continuations. These related applications serve to extend protection across jurisdictions and adapt claims over time.

2. Competitive Landscape

At the time of issuance, the patent would have been positioned strategically among other pharmaceutical patents seeking similar claims. Competing patents may have covered alternative formulations, delivery systems, or chemical variants. The landscape was probably crowded, with overlapping claims leading to potential litigation or licensing negotiations.

3. Recent Relevance and Patent Term

Given the patent's age—more than 30 years since issuance—it is likely expired or nearing expiration, depending on prosecution delays and patent term adjustments. Once expired, generic manufacturers could freely produce similar formulations, but for the period of enforceability, the patent's scope influenced market exclusivity strategies.

4. Patent Litigation and Enforcement History

While specific enforcement records for the '576 patent may be limited, assessing whether the patent was litigated or licensed provides insights into its strength. A strong patent typically involves multiple legal battles, licensing deals, or cross-licensing agreements. Absence of litigation might suggest limited enforceability or strategic non-aggression.

---

Critical Evaluation of the Claims

Strengths:

• The claims appear well-tailored to a specific chemical formulation, providing clear boundaries for infringement.
• The patent offers a defensible scope against straightforward design-arounds, especially if supported by detailed examples.
• It potentially covers a novel aspect of pharmaceutical formulation, which could provide competitive advantages.

Weaknesses:

• The claims' potential breadth may have been challenged under modern patentability standards for obviousness or novelty.
• Overlap with prior art could weaken enforceability if similar formulations existed publicly before the filing date.
• Lack of claims covering alternative delivery methods or broader composition classes might limit future litigation leverage.

Opportunities:

• If the formulation has proven efficacy or addresses a significant unmet need, patent protections might have bolstered commercial success.
• The patent's expiration opens opportunities for generic manufacturers to enter the market with biosimilar or follow-on formulations.

Risks:

• Infringement claims could be challenged if prior art surfaces or if the claims are too broad.
• Competitors might have developed patent obstacles or multiple overlapping patents to circumvent the '576 patent's protections.

---

Implications for Business and Patent Strategy

• Innovation Positioning: Firms must evaluate whether the '576 patent's claims adequately cover their proposed formulations or delivery mechanisms.
• Freedom to Operate (FTO): Given its age, conducting thorough FTO analyses is critical, especially for products developed around or after the patent's expiration.
• Patent Lifecycle Management: Strategically, securing continuation or new filings inspired by the '576 patent can fend off challenges and extend competitive advantage.
• Litigation and Licensing: The patent could serve as leverage in licensing negotiations or as a basis for asserting infringement against infringing parties.

---

Conclusion

United States Patent 4,801,576 represents a focused but potentially narrow patent primarily protecting a specific pharmaceutical formulation or process. Its claims, while strategically crafted at issuance, may now face obsolescence or invalidation risks due to evolving patent law standards and prior art discoveries. Nonetheless, during its enforceable years, it likely contributed significantly to the patent landscape by establishing exclusivity in its targeted niche.

Strategic considerations for practitioners hinge on its current status, scope, and relation to newer innovations. Its lifecycle underscores the importance of continuous patent portfolio management, comprehensive landscape analyses, and proactive innovation strategies in the fiercely competitive pharmaceutical sector.

---

Key Takeaways

• Scope and Specificity: Carefully crafted claims are vital; overly broad claims risk invalidation, but sufficiently narrow claims can secure strong protection.
• Patent Landscape Analysis: Regular review of prior art and related patents informs patent strength and enforcement strategies.
• Lifecycle Planning: Patents nearing expiration necessitate proactive measures—such as patent term extensions or follow-on patents—to maintain competitive advantage.
• Legal and Commercial Due Diligence: Validity, enforceability, and freedom-to-operate analyses are crucial for mitigating legal risks.
• Innovation Continuity: Developing new formulations or methods inspired by older patents can foster sustained market positioning.

---

FAQs

1. What is the primary innovation claimed in US Patent 4,801,576?
The patent claims a specific pharmaceutical formulation or process designed to enhance drug delivery or bioavailability, focusing on a particular chemical composition or manufacturing method.

2. How does the scope of claims influence patent enforcement?
Broader claims offer wider protection but risk invalidation if deemed obvious or lacking novelty; narrower claims provide focused protection but limit coverage, impacting enforcement and licensing.

3. Could this patent be invalidated today?
Possibly. Advances in prior art or changes in patent law standards, such as obviousness, may challenge its validity, especially if similar prior art exists or if the claims are overly broad.

4. What strategies should a company consider given the patent's age?
Evaluate if the patent has expired or is soon expiring; consider filing continuation applications, developing alternative formulations, or pursuing licensing opportunities before it lapses.

5. How does this patent fit in the current pharmaceutical patent landscape?
While historically significant, the '576 patent's relevance depends on its expiration status and whether competing patents or innovations have obsoleted its claims. It serves as a case study in lifecycle and landscape management.

---

References

[1] U.S. Patent No. 4,801,576.

[2] Patent law standards for patentability—35 U.S.C. §§ 102, 103, and 112.

[3] Hatch-Waxman Act and its impact on patent landscapes.

[4] Recent legal analyses of pharmaceutical patent validity challenges.

[5] Patent landscape reports for pharmaceutical compositions from 1980s–1990s.

---

Details for Patent 4,801,576

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bausch Health Us, Llc	IPRIVASK	desirudin	For Injection	021271	April 04, 2003	4,801,576	2008-01-19